Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01690845
Other study ID # 10712010
Secondary ID
Status Recruiting
Phase Phase 2
First received September 16, 2012
Last updated September 21, 2016
Start date June 2012

Study information

Verified date September 2016
Source Medical University of Vienna
Contact Valentin Fuhrmann, Prof
Phone 0043140400
Email valentin.fuhrmann@meduniwien.ac.at
Is FDA regulated No
Health authority Austria: Ethikkommission
Study type Interventional

Clinical Trial Summary

Hypoxic hepatitis (HH) is reported to be the most frequent cause of elevated aminotransferase levels in hospital. Up to 10 % of critically ill patients develop HH during the course of their intensive care unit (ICU) stay. Occurrence of HH is a life threatening event and ICU-mortality is reported to be up to 60%. Early therapeutic intervention is of central prognostic importance in patients with HH to improve the hemodynamic impairment as early as possible, to reduce hyperammonemia and hepatic encephalopathy, to avoid progression of organ failure and to improve outcome. Studies reported that Molecular Adsorbent Recirculating System (MARS®) therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. The study hypothesis is that MARS® therapy in critically ill patients with severe HH improves hepatic hemodynamics and function and consecutively the course of the disease. 40 patients with suffering of severe HH with aminotransferase levels > 40 times the upper limit of normal of more than 12 hours will be randomized 1:1 to MARS® therapy (n=20) or conventional therapy (n=20). 4 MARS®-sessions will be performed on three consecutive days, each for at least 12 hours. Treatment will be continued under special circumstances. The maximum duration of the treatment phase is 7 days. The primary endpoint is the difference of the indocyanine plasma disappearance rate at day 7. The expected duration of the study is 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- presence of severe hypoxic hepatitis with aminotransferase levels > 40 times the upper limit of normal

- duration of hypoxic hepatitis more than 12 hours

- age >/= 18 years

Exclusion Criteria:

- age < 18 years

- pregnancy

- DNR - order

- liver cirrhosis

- Cardiopulmonary resuscitation with unknown neurological outcome and/or hypoxic brain damage

- Expected survival of less than 24 hours

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
MARS
Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.

Locations

Country Name City State
Austria Medical University Vienna, Dpt. of Internal Medicine 3, Div. of Gastroenterology and Hepatology Vienna
Germany University Medical Center Hamburg-Eppendorf Hamburg

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary difference of the indocyanine plasma disappearance rate (ICG-PDR) The primary endpoint will be the difference of the indocyanine plasma disappearance rate (ICG-PDR) at day 7. Only in case of major differences in baseline values of ICG-PDR we will use the change from baseline to day 7 of ICG-PDR (delta ICG-PDR) as outcome. Assuming normal distribution of ICG-PDR, we will formally test the null-hypothesis of no difference between intervention group and control using an independent sample t-test. The assumption of a normal distribution will be founded on visually inspecting a histogram and using the Shapiro Wilks test for normal distribution. If the assumption of normality does not hold data will be compared using the Mann-Whitney U-test. A p-level of < 0.05 will be considered statistically significant. Furthermore a linear random coefficient model will be used to incorporate daily measurements of ICG-PDR during the course of the study in terms of a repeated measures design. Days 1-7 No
Secondary duration of vasopressor support 1-28 No
Secondary ICU - length of stay 1-28 No
Secondary hospital - length of stay 1-90 No
Secondary 7-day mortality 7 days No
Secondary 28 day mortality 28 days No
Secondary number of organ failure on day 7 7 days No
Secondary number of organ failure on day 28 28 days No
Secondary markers of liver function especially occurrence of jaundice (defined as total bilirubin levels > 3 mg/dL) will be documented 1-28 No
Secondary number of vasopressor free days 28 days No
Secondary systemic hemodynamics systemic blood pressure, heart rate, cardiac index, central venous oxygen saturation, systemic vascular resistance index, global enddiastolic volume index, stroke volume variation, extravascular lung water index, pulse pressure variation, intrathoracic blood volume index, cardiac function index, central venous pressure 7 days No
Secondary number of complications of HH following complications will be encountered: cholestasis, secondary sclerosing cholangitis, hepatic encephalopathy grade 3 & 4, hypoglycemia, intraabdominal hypertension, new onset of infections, renal failure, hepatopulmonary syndrome 1-28 Yes
Secondary biomarkers blood samples will be collected the assess markers of inflammation, markers of endothelial function, markers of cardiac function, markers of cholestasis, markers of liver cell necrosis etc 0-28 No
Secondary duration of mechanical ventilation 1-28 No
Secondary necessity of renal replacement therapy 1-28 No
Secondary duration of renal replacement therapy 1-28 No
Secondary 90 days mortality 90 days No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491135 - Hepatocyte Microbeads for Acute Liver Failure Phase 1/Phase 2
Terminated NCT01937130 - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF Phase 2
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Terminated NCT01875874 - Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) Phase 2
Not yet recruiting NCT01435421 - Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery N/A
Completed NCT00245310 - Indocyangreen Elimination in Cirrhosis and Acute Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Active, not recruiting NCT02833064 - Biomarkers in Liver Failure
Not yet recruiting NCT06285253 - miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial Phase 1
Recruiting NCT03882346 - Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients Phase 2
Recruiting NCT05689645 - F573 for Injection for the Treatment of Liver Injury/Failure Phase 2
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Completed NCT00655304 - The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure N/A
Completed NCT00059267 - Prevention of Recurrent Hepatitis B After Liver Transplantation N/A
Active, not recruiting NCT05413083 - Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Withdrawn NCT04089969 - Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct N/A
Completed NCT02460510 - Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF N/A
Completed NCT01872767 - Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure N/A